New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
09:06 EDTLGNDLigand price target raised to $91 from $78 at Summer Street
Summer Street raised its price target for Ligand shares to $91 following the company's Q4 results and 2014 outlook. It keeps a Buy rating on the stock.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
16:14 EDTLGNDLigand names Melanie Herman Interim CFO
Subscribe for More Information
April 22, 2015
12:01 EDTLGNDLigand earns milestone payment from Sage Therapeutics for SAGE-547
Ligand (LGND) announced that it has earned a $500,000 milestone payment from SAGE Therapeutics (SAGE) relating to the treatment of the first patient in SAGE’s Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus and to evaluate the safety of SAGE-547 in patients with SRSE. SAGE has reported that the results from this clinical trial, along with results from SAGE's planned Phase 3 placebo-controlled clinical trial - called the STATUS Trial – and other clinical data obtained from the SAGE-547 development program are intended to form the basis of a New Drug Application submission.
April 21, 2015
09:16 EDTLGNDTG Therapeutics data positive, says Roth Capital
Subscribe for More Information
April 20, 2015
07:41 EDTLGNDLigand partner TG Therapeutics presents pre-clinical data on IRAK4 compounds
Subscribe for More Information
April 15, 2015
07:41 EDTLGNDEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use